首页 / 产品 / 抗体 / 一抗

Rabbit Polyclonal PSMD12 Antibody

  • 中文名: PSMD12抗体
  • 别    名: p55; Rpn5; STISS
货号: IPDX09918
Price: ¥1180
数量:
大包装询价

验证与应用

应用及物种
WB 咨询技术 Human,Mouse,Rat
IF 咨询技术 Human,Mouse,Rat
IHC 1/40-1/200 Human,Mouse,Rat
ICC 技术咨询 Human,Mouse,Rat
FCM 咨询技术 Human,Mouse,Rat
Elisa 1/5000-1/10000 Human,Mouse,Rat

产品详情

参考文献

以下是3篇关于PSMD12抗体的参考文献概览(虚构示例,供参考):

---

1. **文献名称**: *PSMD12 regulates proteasome activity and cancer cell survival via deubiquitination*

**作者**: Chen L, et al.

**摘要**: 本研究利用PSMD12特异性抗体进行免疫沉淀和Western blot分析,发现PSMD12通过调控蛋白酶体去泛素化酶活性影响肿瘤细胞凋亡,抗体验证了其在结直肠癌细胞中的高表达。

---

2. **文献名称**: *Antibody-based profiling of 26S proteasome subunits in neurodegenerative models*

**作者**: Smith K, et al.

**摘要**: 通过商业化PSMD12抗体的免疫组化实验,揭示阿尔茨海默病模型中蛋白酶体亚基PSMD12的异常聚集,提示其与tau蛋白降解障碍的相关性。

---

3. **文献名称**: *CRISPR screening identifies PSMD12 as a critical factor in antiviral immunity*

**作者**: Wang Y, et al.

**摘要**: 结合PSMD12抗体进行功能验证,发现PSMD12敲除显著降低免疫细胞蛋白酶体活性,影响病毒抗原呈递,为抗病毒治疗提供新靶点。

---

注:以上为模拟内容,实际文献需通过PubMed等平台检索(可尝试关键词:**PSMD12 antibody proteasome**)。

背景信息

The PSMD12 antibody is a research tool targeting the PSMD12 protein, a key component of the 26S proteasome. PSMD12 (Proteasome 26S Subunit, Non-ATPase 12), also known as RPN5. is part of the 19S regulatory particle within the ubiquitin-proteasome system (UPS). This system governs intracellular protein degradation, critical for regulating cell cycle progression, apoptosis, and signal transduction. PSMD12 functions as a non-ATPase subunit in the 19S base, assisting in substrate recognition, deubiquitination, and translocation of ubiquitinated proteins into the proteolytic 20S core. Dysregulation of PSMD12 has been implicated in cancer, neurodegenerative disorders, and autoimmune diseases due to its role in maintaining protein homeostasis.

PSMD12 antibodies are widely used in Western blotting, immunohistochemistry, and immunoprecipitation to study protein expression, localization, and interactions. They help elucidate PSMD12's involvement in disease mechanisms, such as tumorigenesis linked to proteasome overactivity or neurodegeneration caused by impaired protein clearance. Recent studies also explore PSMD12 as a potential therapeutic target, with inhibitors under investigation for cancer treatment. When selecting a PSMD12 antibody, researchers prioritize specificity validated via knockout controls, cross-reactivity across species (e.g., human, mouse), and compatibility with intended applications. Commercial antibodies are typically developed in rabbit or mouse hosts, with monoclonal and polyclonal options available for diverse experimental needs.

客户数据及评论

折叠内容

大包装询价

×